A fast hydrogen sulfide-releasing donor increases the tumor response to radiotherapy

Molecular Cancer Therapeutics

Volumn 15, Issue 1, 2016, Pages 154-161

  De Preter, Géraldine ^a   Deriemaeker, Caroline ^a   Danhier, Pierre ^a   Brisson, Lucie ^a   Pham, Thanh Trang Cao ^a   Gre Égoire, Vincent ^a   Jordan, Bénédicte F ^a   Sonveaux, Pierre ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN SULFIDE; ADENOSINE TRIPHOSPHATE; GLUCOSE; RADIOSENSITIZING AGENT; SODIUM BISULFIDE; SULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIMETRY; OXYGEN TENSION; PH; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOSENSITIZATION; RESPIRATORY CHAIN; TREATMENT RESPONSE; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HYPOXIA; METABOLISM; NEOPLASMS; OXYGEN CONSUMPTION; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; HUMANS; HYDROGEN SULFIDE; HYPOXIA; MICE; NEOPLASMS; OXYGEN CONSUMPTION; RADIATION-SENSITIZING AGENTS; SULFIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958154940     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0691-T     Document Type: Article

References (41)

1. Wang R. Hydrogen sulfide: the third gasotransmitter in biology and medicine. Antioxid Redox Signal 2010;12:1061-4.
2. Collman JP, Ghosh S, Dey A, Decreau RA. Using a functional enzyme model to understand the chemistry behind hydrogen sulfide induced hibernation. Proc Natl Acad Sci U S A 2009;106:22090-5.
3. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 2001;20: 6008-16.
4. Zhang Z, Huang H, Liu P, Tang C, Wang J. Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening K ATP channels. Can J Physiol Pharmacol 2007;85:1248-53.
5. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012;92:791-896.
6. Song ZJ, Ng MY, Lee Z-W, Dai W, Hagen T, Moore PK, et al. Hydrogen sulfide donors in research and drug development. Med Chem Comm 2014;5:557-70.
7. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007;6:917-35.
8. Cai WJ, Wang MJ, Ju LH, Wang C, Zhu YC. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int 2010;34:565-72.
9. Wu YC, Wang XJ, Yu L, Chan FK, Cheng AS, Yu J, et al. Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PLoS One 2012;7:e37572.
10. Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 2011;6:e21077.
11. SzaboC,HellmichMR. Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. Cell Cycle 2013;12:2915-6.
12. Zhang J, Xie Y, Xu Y, Pan Y, Shao C. Hydrogen sulfide contributes to hypoxia-induced radioresistance on hepatoma cells. J Radiat Res 2011;52: 622-8.
13. Jordan BF, Gregoire V, Demeure RJ, Sonveaux P, Feron O, O'Hara J, et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62: 3555-61.
14. Jordan BF, Sonveaux P, Feron O, Gregoire V, Beghein N, Gallez B. Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int J Radiat Oncol Biol Phys 2003;55:1066-73.
15. Sonveaux P, Jordan BF, Gallez B, Feron O. Nitric oxide delivery to cancer: why and how? Eur J Cancer 2009;45:1352-69.
16. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009;9:442-58.
17. Harada H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res 2011;52:545-56.
18. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
19. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9: 539-49.
20. James PE, Jackson SK, Grinberg OY, SwartzHM.The effects of endotoxin on oxygen consumption of various cell types in vitro: an EPR oximetry study. Free Radic Biol Med 1995;18:641-7.
21. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 2004;17:240-62.
22. Gallez B, Jordan BF, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42: 627-30.
23. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P,DeWever J, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
24. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal 2010;12:1065-77.
25. Nagy P, Palinkas Z, Nagy A, Budai B, Toth I, Vasas A. Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim Biophys Acta 2014;1840:876-91.
26. Szabo C, Ransy C, Modis K, Andriamihaja M, Murghes B, Coletta C, et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br J Pharmacol 2014;171:2099-122.
27. Yang G. Hydrogen sulfide in cell survival: a double-edged sword. Expert Rev Clin Pharmacol 2011;4:33-47.
28. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
29. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27: 441-64.
30. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011;2:49.
31. Lee ZW, Teo XY, Tay EY, Tan CH, Hagen T, Moore PK, et al. Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance. Br J Pharmacol 2014;171:4322-36.
32. Hu LF, Li Y, Neo KL, Yong QC, Lee SW, Tan BK, et al. Hydrogen sulfide regulates Na+/H +exchanger activity via stimulation of phosphoinositide 3-kinase/Akt and protein kinase G pathways. J Pharmacol Exp Ther 2011;339:726-35.
33. Madshus IH. Regulation of intracellular pH in eukaryotic cells. Biochem J 1988;250:1-8.
34. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010;14:771-94.
35. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996;56:1194-8.
36. Nicholls P, Kim JK. Sulphide as an inhibitor and electron donor for the cytochrome c oxidase system. Can J Biochem 1982;60:613-23.
37. Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995;34:313-6.
38. Diepart C, Karroum O, Magat J, Feron O, Verrax J, Calderon PB, et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res 2012;72:482-90.
39. Zlotecki RA, Baxter LT, Boucher Y, Jain RK. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis andmechanistic interpretation. Microvasc Res 1995;50:429-43.
40. Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function. Am J Physiol Cell Physiol 2011;300:C951-67.
41. Koenitzer JR, Isbell TS, Patel HD, Benavides GA, Dickinson DA, Patel RP, et al. Hydrogen sulfide mediates vasoactivity in an O2-dependent manner. Am J Physiol Heart Circ Physiol 2007;292:H1953-60.